Bausch Health Companies Inc. (TSE:BHC - Free Report) - Equities researchers at Zacks Research boosted their Q1 2025 earnings per share estimates for Bausch Health Companies in a research note issued on Monday, January 20th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.25 per share for the quarter, up from their prior forecast of $1.22. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q2 2025 earnings at $1.49 EPS, Q1 2026 earnings at $1.58 EPS, Q2 2026 earnings at $1.65 EPS and Q3 2026 earnings at $1.98 EPS.
Bausch Health Companies (TSE:BHC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported C$1.53 earnings per share (EPS) for the quarter, topping the consensus estimate of C$1.43 by C$0.10. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. The firm had revenue of C$3.42 billion during the quarter, compared to the consensus estimate of C$3.36 billion.
Separately, Evercore ISI raised shares of Bausch Health Companies to a "hold" rating in a research report on Tuesday, October 15th.
Check Out Our Latest Research Report on BHC
Bausch Health Companies Stock Up 3.8 %
BHC stock traded up C$0.41 during midday trading on Wednesday, reaching C$11.12. The company had a trading volume of 361,717 shares, compared to its average volume of 185,273. The company has a market capitalization of C$4.08 billion, a P/E ratio of -6.35, a PEG ratio of 0.21 and a beta of 0.77. Bausch Health Companies has a 1 year low of C$5.45 and a 1 year high of C$15.43. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of 7,583.76. The company has a 50 day moving average of C$11.24 and a two-hundred day moving average of C$10.33.
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
See Also
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
